Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 184

1.

Somatic copy number alterations by whole-exome sequencing implicates YWHAZ and PTK2 in castration-resistant prostate cancer.

Menon R, Deng M, Rüenauver K, Queisser A, Peifer M, Offermann A, Boehm D, Vogel W, Scheble V, Fend F, Kristiansen G, Wernert N, Oberbeckmann N, Biskup S, Rubin MA, Shaikhibrahim Z, Perner S.

J Pathol. 2013 Dec;231(4):505-16. doi: 10.1002/path.4274. Erratum in: J Pathol. 2014 May;233(1):101. Pfeifer, Martin [corrected to Peifer, Martin].

PMID:
24114522
2.

Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity.

Beltran H, Yelensky R, Frampton GM, Park K, Downing SR, MacDonald TY, Jarosz M, Lipson D, Tagawa ST, Nanus DM, Stephens PJ, Mosquera JM, Cronin MT, Rubin MA.

Eur Urol. 2013 May;63(5):920-6. doi: 10.1016/j.eururo.2012.08.053. Epub 2012 Sep 5.

3.

Exome enrichment and SOLiD sequencing of formalin fixed paraffin embedded (FFPE) prostate cancer tissue.

Menon R, Deng M, Boehm D, Braun M, Fend F, Boehm D, Biskup S, Perner S.

Int J Mol Sci. 2012;13(7):8933-42. doi: 10.3390/ijms13078933. Epub 2012 Jul 17.

4.

Prognostic significance of YWHAZ expression in localized prostate cancer.

Rüenauver K, Menon R, Svensson MA, Carlsson J, Vogel W, Andrén O, Nowak M, Perner S.

Prostate Cancer Prostatic Dis. 2014 Dec;17(4):310-4. doi: 10.1038/pcan.2014.32. Epub 2014 Aug 26.

PMID:
25156059
5.

Integrative molecular profiling of routine clinical prostate cancer specimens.

Grasso CS, Cani AK, Hovelson DH, Quist MJ, Douville NJ, Yadati V, Amin AM, Nelson PS, Betz BL, Liu CJ, Knudsen KE, Cooney KA, Feng FY, McDaniel AS, Tomlins SA.

Ann Oncol. 2015 Jun;26(6):1110-8. doi: 10.1093/annonc/mdv134. Epub 2015 Mar 3.

6.

Integrative molecular profiling reveals asparagine synthetase is a target in castration-resistant prostate cancer.

Sircar K, Huang H, Hu L, Cogdell D, Dhillon J, Tzelepi V, Efstathiou E, Koumakpayi IH, Saad F, Luo D, Bismar TA, Aparicio A, Troncoso P, Navone N, Zhang W.

Am J Pathol. 2012 Mar;180(3):895-903. doi: 10.1016/j.ajpath.2011.11.030. Epub 2012 Jan 11.

7.

Expression screening of cancer/testis genes in prostate cancer identifies NR6A1 as a novel marker of disease progression and aggressiveness.

Mathieu R, Evrard B, Fromont G, Rioux-Leclercq N, Godet J, Cathelineau X, Guillé F, Primig M, Chalmel F.

Prostate. 2013 Jul;73(10):1103-14. doi: 10.1002/pros.22659. Epub 2013 Mar 26.

PMID:
23532770
8.

Detection of somatic copy number alterations in cancer using targeted exome capture sequencing.

Lonigro RJ, Grasso CS, Robinson DR, Jing X, Wu YM, Cao X, Quist MJ, Tomlins SA, Pienta KJ, Chinnaiyan AM.

Neoplasia. 2011 Nov;13(11):1019-25.

9.

Y-box binding protein-1 promotes castration-resistant prostate cancer growth via androgen receptor expression.

Shiota M, Takeuchi A, Song Y, Yokomizo A, Kashiwagi E, Uchiumi T, Kuroiwa K, Tatsugami K, Fujimoto N, Oda Y, Naito S.

Endocr Relat Cancer. 2011 Jul 11;18(4):505-17. doi: 10.1530/ERC-11-0017. Print 2011 Aug.

10.

PTEN deletion and heme oxygenase-1 overexpression cooperate in prostate cancer progression and are associated with adverse clinical outcome.

Li Y, Su J, DingZhang X, Zhang J, Yoshimoto M, Liu S, Bijian K, Gupta A, Squire JA, Alaoui Jamali MA, Bismar TA.

J Pathol. 2011 May;224(1):90-100. doi: 10.1002/path.2855. Epub 2011 Mar 7.

PMID:
21381033
11.

Targeted high throughput sequencing in clinical cancer settings: formaldehyde fixed-paraffin embedded (FFPE) tumor tissues, input amount and tumor heterogeneity.

Kerick M, Isau M, Timmermann B, Sültmann H, Herwig R, Krobitsch S, Schaefer G, Verdorfer I, Bartsch G, Klocker H, Lehrach H, Schweiger MR.

BMC Med Genomics. 2011 Sep 29;4:68. doi: 10.1186/1755-8794-4-68.

12.

Exome sequencing of prostate cancer supports the hypothesis of independent tumour origins.

Lindberg J, Klevebring D, Liu W, Neiman M, Xu J, Wiklund P, Wiklund F, Mills IG, Egevad L, Grönberg H.

Eur Urol. 2013 Feb;63(2):347-53. doi: 10.1016/j.eururo.2012.03.050. Epub 2012 Mar 31.

PMID:
22502944
13.

Identification of docetaxel resistance genes in castration-resistant prostate cancer.

Marín-Aguilera M, Codony-Servat J, Kalko SG, Fernández PL, Bermudo R, Buxo E, Ribal MJ, Gascón P, Mellado B.

Mol Cancer Ther. 2012 Feb;11(2):329-39. doi: 10.1158/1535-7163.MCT-11-0289. Epub 2011 Oct 25.

14.

Common structural and epigenetic changes in the genome of castration-resistant prostate cancer.

Friedlander TW, Roy R, Tomlins SA, Ngo VT, Kobayashi Y, Azameera A, Rubin MA, Pienta KJ, Chinnaiyan A, Ittmann MM, Ryan CJ, Paris PL.

Cancer Res. 2012 Feb 1;72(3):616-25. doi: 10.1158/0008-5472.CAN-11-2079. Epub 2011 Dec 7.

15.

New therapies for castration-resistant prostate cancer: efficacy and safety.

Beltran H, Beer TM, Carducci MA, de Bono J, Gleave M, Hussain M, Kelly WK, Saad F, Sternberg C, Tagawa ST, Tannock IF.

Eur Urol. 2011 Aug;60(2):279-90. doi: 10.1016/j.eururo.2011.04.038. Epub 2011 May 4. Review.

PMID:
21592649
16.

Human heterochromatin protein 1 isoform HP1beta enhances androgen receptor activity and is implicated in prostate cancer growth.

Shiota M, Song Y, Yokomizo A, Tada Y, Kuroiwa K, Eto M, Oda Y, Inokuchi J, Uchiumi T, Fujimoto N, Seki N, Naito S.

Endocr Relat Cancer. 2010 May 18;17(2):455-67. doi: 10.1677/ERC-09-0321. Print 2010 Jun.

17.

Amplification and overexpression of vinculin are associated with increased tumour cell proliferation and progression in advanced prostate cancer.

Ruiz C, Holz DR, Oeggerli M, Schneider S, Gonzales IM, Kiefer JM, Zellweger T, Bachmann A, Koivisto PA, Helin HJ, Mousses S, Barrett MT, Azorsa DO, Bubendorf L.

J Pathol. 2011 Mar;223(4):543-52. doi: 10.1002/path.2828. Epub 2011 Jan 5.

PMID:
21294127
18.

ERG protein expression and gene rearrangements are present at lower rates in metastatic and locally advanced castration-resistant prostate cancer compared to localized disease.

Teng LH, Wang C, Bégin LR, Dolph M, Yilmaz A, Trpkov K, Donnelly B, Bismar TA.

Urology. 2013 Aug;82(2):394-9. doi: 10.1016/j.urology.2013.03.029. Epub 2013 Jun 6.

PMID:
23746715
19.

Overexpression and gene amplification of BAG-1L in hormone-refractory prostate cancer.

Mäki HE, Saramäki OR, Shatkina L, Martikainen PM, Tammela TL, van Weerden WM, Vessella RL, Cato AC, Visakorpi T.

J Pathol. 2007 Aug;212(4):395-401.

PMID:
17503439
20.

Formamide as a denaturant for bisulfite conversion of genomic DNA: Bisulfite sequencing of the GSTPi and RARbeta2 genes of 43 formalin-fixed paraffin-embedded prostate cancer specimens.

Zon G, Barker MA, Kaur P, Groshen S, Jones LW, Imam SA, Boyd VL.

Anal Biochem. 2009 Sep 15;392(2):117-25. doi: 10.1016/j.ab.2009.06.001. Epub 2009 Jun 6.

PMID:
19505431

Supplemental Content

Support Center